An Observational Study to Evaluate the Safety and Efficacy of Cetuximab in Combination With Platinum-based Chemotherapy in the First-line Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck
NCT ID: NCT01142869
Last Updated: 2017-05-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
133 participants
OBSERVATIONAL
2009-12-31
2014-08-05
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cetuximab (Erbitux) in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First Line Treatment of Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (EXTREME)
NCT00122460
A Post-marketing Surveillance Study on Erbitux in Combination With Platinum-based Chemotherapy in Metastatic/Recurrent Squamous Cell Cancer of the Head and Neck
NCT01075841
A Post Marketing Surveillance Study to Assess the Safety and Efficacy of Cetuximab Plus Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck
NCT01303237
Study of Cetuximab in Combination With Chemotherapy in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
NCT00971932
Cetuximab (ERBITUX®) Added to Two Concurrent Chemoradiotherapy Platforms in Locally Advanced Head and Neck Cancer
NCT00468169
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cetuximab
The starting dose will be intravenous (IV) cetuximab 400 mg/m2 body surface area administered as a 120-minute infusion once a week . The subsequent weekly doses will be IV cetuximab 250 mg/m2 administered as a 60-minute infusion. The maximum infusion rate must not exceed 10 mg/min.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Merck Ltd., India
INDUSTRY
Merck KGaA, Darmstadt, Germany
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dr. Rajiv Rana
Role: STUDY_DIRECTOR
Merck Ltd., India
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ambaa Hospitals
Hyderabad, Andhra Pradesh, India
Indo- American Cancer Institute & Research Centre
Hyderabad, Andhra Pradesh, India
NVS Ramakrishna's Clinic
Hyderabad, Andhra Pradesh, India
Dr. Nikhil's Clinic
Secunderabad, Andhra Pradesh, India
Swarna Sai Hospital
Secunderabad, Andhra Pradesh, India
Sparsh Hospital
Orissa, Bhubaneswar, India
Wellness Consultants Clinic
Surat, Gujarat, India
Global Health Pvt Ltd
Gurgaon, Haryana, India
The Cancer Clinic
Kochi, Kerala, India
Dr. T. P. Sahoo's Clinic
Bhopal, Madhya Pradesh, India
BND Onco Centre
Mumbai, Maharashtra, India
S.L.Raheja Hospital
Mumbai, Maharashtra, India
S M Karandikar's Clinic
Pune, Maharashtra, India
Ruby Hall Clinic
Pune, Maharashtra, India
Galaxy Care Laproscopic Institute
Pune, Maharashtra, India
Neigrihms
Shillong, Meghālaya, India
Grace Nursing Home
Aizawl, Mizoram, India
All India Institute of Medical Sciences
New Delhi, National Capital Territory of Delhi, India
Cancer Clinic
Jaipur, Rajasthan, India
SMS Hospital
Jaipur, Rajasthan, India
Bhagwan Mahaveer Cancer Hospital
Jaipur, Rajasthan, India
J.K.Cancer Institute
Kanpur, Uttar Pradesh, India
Annapurna Medical and Cancer Relief Society
Lucknow, Uttar Pradesh, India
Dr. Vineet's Clinic
New Delhi, Uttar Pradesh, India
SMH-Curie Cancer Centre, Shanti Mukand Hospital
New Delhi, Uttar Pradesh, India
B.R. Singh Hospital
Kolkata, West Bengal, India
Apollo Gleneagles Cancer Hospital
Kolkata, West Bengal, India
Sunil Gupta's Clinic
Delhi, , India
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EMR 062202-514
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.